MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II-III NSCLC

Cemiplimab plus ipilimumab for advanced NSCLC

Autologous tumour infiltrating lymphocytes cell therapy in metastatic non-small cell lung cancer

Incorporating KRAS as a novel biomarker: Challenges and opportunities

Real world data and diagnostics in patients with NSCLC with EGFR exon 20 insertions

Durvalumab following radiotherapy in patients with unresectable, stage 3 NSCLC ineligible for chemotherapy

OncoAlert and ecancer weekly roundup for March 01 - 06, 2021

Managing the treatment of NSCLC patients during the COVID-19 pandemic (FR)

Managing the treatment of NSCLC patients during the COVID-19 pandemic (DE)

Managing the treatment of NSCLC patients during the COVID-19 pandemic (IT)

Managing the treatment of NSCLC patients during the COVID-19 pandemic (ES)

Reducing the risk of contracting COVID-19 in patients with NSCLC (FR)